Natera Q3 2022 Earnings Investor Presentation

Natera's Q3 2022 earnings presentation reports $210.6M in total revenue with 33% YoY growth and 518K tests processed. The company highlighted strong momentum in oncology testing with 53K Signatera tests (150%+ YoY growth) and expanded reimbursement coverage, while announcing updated full-year revenue guidance of $810M-$830M.